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Abstract
In drug delivery, there is often a trade-off between effective killing of the pathogen, and harmful side effects associated with
the treatment. Due to the difficulty in testing every dosing scenario experimentally, a computational approach will be
helpful to assist with the prediction of effective drug delivery methods. In this paper, we have developed a data-driven
predictive system, using machine learning techniques, to determine, in silico, the effectiveness of drug dosing. The system
framework is scalable, autonomous, robust, and has the ability to predict the effectiveness of the current drug treatment
and the subsequent drug-pathogen dynamics. The system consists of a dynamic model incorporating both the drug
concentration and pathogen population into distinct states. These states are then analyzed using a temporal model to
describe the drug-cell interactions over time. The dynamic drug-cell interactions are learned in an adaptive fashion and used
to make sequential predictions on the effectiveness of the dosing strategy. Incorporated into the system is the ability to
adjust the sensitivity and specificity of the learned models based on a threshold level determined by the operator for the
specific application. As a proof-of-concept, the system was validated experimentally using the pathogen Giardia lamblia and
the drug metronidazole in vitro.
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Introduction
A fundamental principle underlying effective treatment of a
pathogen is the trade-off between rapidly curing the disease and
preventing harm to the patient induced by the treatment.
Currently, due to the expense associated with drug testing and
the infeasibility of testing every possible dose experimentally,
treatments are very difficult or impossible to optimize with respect
to the balance between patient toxicity and pathogen killing.
Another factor to consider when balancing this trade-off is
mutation within the natural population, or specific drug induced
mutation. The emergence of drug resistant strains of pathogens,
including hepatitis B virus, methicillin resistant Staphylococcus aureus
(MRSA), and tuberculosis, have had a dramatic impact on world
health [1,2,3,4]. The CDC estimates that 94,360 cases of MRSA
occur each year in the U.S. alone resulting in 18,360 deaths [5].
The emergence of many drug resistant strains has been linked to
patient non-compliance, due to undesirable side-effects associated
with the treatment [6]. When the patient begins to feel better, they
stop taking the drug so that side-effects can be avoided. This will
allow the pathogen to recover and increase the potential for a drug
resistant strain to emerge. In order to determine a more thorough
approach to selecting the optimum dose, thus minimizing
excessive drug, machine learning techniques were used to develop
a framework for analyzing the trade-off between the drug dosage
and effective pathogen killing.
The proposed system works as follows. First, the drug dose and
cell population are discretized into distinct states. Then, the state
changes are analyzed over time. After a Probabilistic Suffix
Automaton (PSA) model makes sequential prediction of the drug-
cell dynamics based on current observations, the future drug-cell
dynamics are predicted given current observations of the drug
dose and pathogen population. The combined framework can
predict future drug-pathogen dynamics based on current obser-
vations and also determine the effectiveness of a drug delivery
method based on the experimental training data. The overall
framework was developed to meet the following criteria:
N Scalability – the system must be able to scale to multiple drugs
and pathogen interactions. Due to the difficulty in scaling
ordinary differential equations with multiple drugs [7],
machine learning algorithms were employed.
N Minimum human supervision – the system must be able to
learn and predict the drug-pathogen dynamics in an
unsupervised, autonomous fashion. This will represent an
improvement on other supervised, rule-based expert systems
[8].
N Adaptivity – the system must be able to adapt to a constantly
evolving pathogen population. As opposed to Hidden Markov
Models, which are fixed after the initial training [9], a data-
driven Variable Length Markov Model (VLMM) was used for
increased flexibility.
N Online learning – the system must be able to interpret dynamic
drug-pathogen sample points instead of dealing with a static
dataset. Since offline learning algorithms such as Bayesian
were not suitable [10], online learning algorithms were
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developed using a Fuzzy C-Mean (FCM) clustering technique
and VLMM.
To validate the proposed system, we have used Giardia lamblia
and metronidazole as a test case. Giardia is a protozoan parasite of
the intestinal tract of mammals, reptiles, and birds, and the
causative agent of giardiasis [11]. Currently, Giardia is responsible
for the largest number of waterborne outbreaks of diarrhea in the
United States and infects approximately 2% of adults and 6 to 8%
of children in developed countries [12,13]. The incidence of
infection greatly increases in countries with poor water treatment
facilities, and can lead to death in children in poverty stricken
areas. Since the late 1950s, metronidazole and other nitroimida-
zoles have been used for treatment of giardiasis [14,15]. However,
drug resistance to metronidazole has been observed in humans,
resulting in a failure of treatment [16]. As described earlier, the
emergence of metronidazole resistant Giardia strains has been
linked to the severity of side-effects, often lead to patients
discontinuing the treatment after feeling better [17]. Since the
mechanism leading to drug resistance in Giardia is patient non-
compliance due to harsh side-effects, this serves as an ideal test
case to validate the framework.
The goal of this research was to develop a methodology for an in
silico approach to test multiple dosing options with a limited set of
experimental data. Using Giardia as an in vitro test case, the cell
count after various doses of metronidazole was used to generate
both the training and testing data sets. Based on these data sets, a
system was developed to classify the drug dosage and cell
population into distinct classes, and predict the future states from
current observations and effectiveness of treatment. While this
study has focused only on in vitro applications, the method
developed herein, has the potential to be extended to a clinical
setting, to help doctors, with limited data, to predict if a current
dosing method was effective or ineffective. This paper represents
an important first step in the incorporation of machine learning
technique to address the complex problem of pathogen drug
resistance and effective therapy.
Materials and Methods
1.1 System architecture
Figure 1 shows the architecture of the sequential drug delivery
prediction framework. The drug concentration and pathogen
population were used as a two-dimensional vector input. First the
input was clustered into categories using a FCM clustering
algorithm (described in Section 1.2). After categorization, the
temporal patterns of the drug-pathogen dynamics were analyzed
using a VLMM model that was implemented in the form of a PSA
(described in Section 1.3). The system was able to make two
kinds of predictions based on the PSA model: 1) the drug-pathogen
dynamics over time, based on current observations (Section 1.4),
and 2) the effectiveness of the drug using a likelihood-ratio detector
(Section 1.5). In this paper, online, unsupervised learning was
used since the pathogen was capable of evolving over time under
selective pressures. All learning algorithms used were data-driven
and adaptable.
1.2 Categorize drug-pathogen dynamics using an FCM
clustering technique
Typically in the medical and drug delivery fields, FCM
clustering algorithms have been used in analysis of medical
imaging, including PET, MRI, and CAT scans [18,19,20].
However, in this study, an FCM clustering algorithm was used
to categorize the drug concentration and the pathogen population
into distinct categories. A major advantage of the FCM clustering
technique is its fuzziness, in which a single data pattern may
belong to several clusters, having different membership values in
each cluster. This property could be advantageous when dealing
with noisy or incomplete data, common in typical drug delivery
applications. In this paper, an FCM clustering algorithm was
developed similar to Dunn’s [21], which was improved upon by
Bezdek [22]. The algorithm is described as follows.
Given a set of N data observations, i.e., X~fx1,:::,xNg, and a
number of desired clusters C. The FCM clustering algorithm
minimizes the following objective function:
Jm~
XN
i~1
XC
j~1
umij xi{cj
 2, ð1Þ
where uij is the degree of membership of xi in the cluster j. xi is the
i-th D-dimensional input vector, cj is the prototype of the center of
cluster j, m is a weighting exponent on each fuzzy membership
such that 2ƒmƒ?, and xi{cj
 2 is a distance measurement
between the data xi and cluster center cj . The objective function
Jm is minimized via an iterative process. The update function for
the cluster centers uij is defined as follows:
Figure 1. Diagram of the proposed machine learning procedure. The top part of the diagram shows the training procedure, which contains
the clustering module and temporal analysis module. The bottom part shows the testing procedure.
doi:10.1371/journal.pone.0031724.g001
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uij~
1
PC
k~1
( xi{cj
  xi{ckk k) 2m{1
: ð2Þ
The update function for the cluster center prototype cj is defined
as follows:
cj~
PN
i~1
umij xi
PN
i~1
umij
, ð3Þ
where Viuij satisfies: uij[½0,1, and 0v
Pn
j~1 uijvN . Iteration will
stop, when maxijf u(qz1)ij {u(q)ij
 gvr, where r is a termination
criterion between 0 and 1, whereas q is the iteration step. This
procedure converges to a local minimum or a saddle point of Jm.
In terms of the drug delivery system, xi represents the
combination of the cell population and drug concentration at
each observation point for N number of observations. For
example, if there are 24 trials in the training dataset, with 10
observation points in each trial, then N is equal to 240. From these
240 points, natural clusters, groups of similar observations, were
identified. The total number of observations is then classified into
individual states, cj , from 1 to C, where C is the total number of
desired states. The value of C can be selected in collaboration with
experimental researchers to yield a set of states that have biological
meaning. For example, if the goal was to evaluate effective and
non-effective only, then C would equal 2. However, for
applications that require diverse analysis, C could be set to a
higher value. The Fuzzy function was used to increase the
robustness of the clustering procedure due to potentially noisy
experimental data. This function allows for partial membership in
multiple clusters, instead of forcing membership to only one
cluster. After the training procedure, the state prototypes are
obtained, and the prototypes are used to analyze the testing data.
Note that the FCM technique allows the model to scale to multiple
drugs by increase the dimensionality of X . By incorporating
multiple drug concentrations with pathogen populations into
clustering models, each cluster can then represent the multi-drug
effects on pathogen population change.
In the testing procedure, the drug-pathogen observations, O, are
categorized during the prediction phase, described as follows:
given C distinct category/state prototypes, denoted by
C~fc1,:::,cjg, learned during the training phase, and a series of
Tobservations O~fo1:::ot:::oT : t[Tg made over time, where t
denotes the time index, the system finds the closest match of the
current observation otto a state prototype in cj . The formulation is
defined as follows,
ot[ci if i~arg maxkP(ckjot), ð4Þ
where P(ckjot)vr, which means that the difference between
otand the closest match P(ckjot)is less than a vigilance parameter
r. If this is the case, then the drug-pathogen observation ot is
categorized as i. If the difference is larger than r, then a new drug-
pathogen dynamic state will be generated. If we let st denote the
state label learned from observation ot, at time t, then there is a
one-to-one mapping from observations to state labels. Thus, a
sequence of observations O, becomes a sequence of states
S~fs1:::st:::sT : st[C,t[Tg.
Using the methods described above, it was possible to categorize
the observations of the cell-drug interactions into clearly defined
states. These states contain information about the cell population
and drug concentration at each observation point, but contain no
temporal information. To analyze the temporal pattern associated
with the changes between states, it was necessary to use another
technique to obtain this information.
1.3 Analyze temporal pattern using VLMM model
As described above, FCM categorizes the data into state
sequences, which are often temporally correlated. To analyze
these temporal dependencies, a Markov chain model was used.
Since Markov models have difficulty in capturing higher level
dependencies in the sequence data, we chose to use a high order
(memory) Markov model. For a large set of time-correlated
sequential data, statistical correlations decrease rapidly with
increasing distance between symbols in the sequence. If the
statistical correlations are indeed decreasing, then there exists a
memory length L such that the empirical probability changes very
little if conditioned on subsequences longer than L. In other
words, the memory length depends on the context and is not fixed.
In this study, a VLMM model [23] was used to preserve the
minimal subsequences (of variable lengths) that are necessary for
precise modeling of the given statistical source. This results in a
more flexible and efficient sequence representation.
In addition, a symbolic predictive PSA model was constructed
in this work to interpret and predict data based on the drug/
pathogen dynamics. In the PSA model, the continuous time
observations were first abstracted to a discrete space, analogous to
a set of finite states. Symbolic modeling and processing have
several advantages over continuous measurements and models in
drug-pathogen dynamics, including: 1) discrete states have clear
physical meaning and are easy for humans to interpret, e.g., drug
effective state; and 2) are less impacted from noise, while still
preserving the essential underlying pattern or dependencies that
govern the behavior in the observed domain. These advantages of
the PSA model make it more suitable to model temporal sequences
in drug-pathogen dynamics, compared to other models.
In general, each state in a PSA is labeled by a string of state
sequences over a finite alphabet S. The transition function
between the states is defined based on these state sequence labels.
Given a state sequence s, the algorithm traverses the underlying
graph of the PSA, and ends in a state labeled by a suffix of the
sequence. When a PSA generates a state sequence, the probability
distribution of the next symbol generated is defined given the
previously generated subsequence of length, at most, L. Therefore,
the probability distributions these automata generate can be
equivalently generated by Markov chains of order L. However,
since the size of order-L Markov chains is exponential in L, their
estimation requires a data length and time exponential in L.
For any drug delivery trial, the state at each observation point is
combined to form the state sequence. s~s1:::sl , si[S, the longest
suffix of s can be denoted as suffix(s)~fsi:::sl j1ƒiƒlg|feg.
The PSA l is a 5-tuple, (Q,S,d,c,p), consisting of
N a finite set of states Q (e.g., natural states of drug-pathogen
interactions),
N a finite alphabet S, in this scenario, the number associated
with each state (e.g., 1,2,3,…)
N a transition function d : Q|S?Q, which describes the
transition from one state to another. For example the
transition from a high drug, high pathogen state to a low
drug, low pathogen state.
N the next symbol probability function c : Q|S?½0,1,
Data-Driven Predictive Approach for Drug Delivery
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N and an initial probability distribution over the starting states
p : Q?½0,1.
Note that the function c and p must satisfy the following
conditions for every q[Q,Ss[Sc(q,s)~1 and Sq[Qp(q)~1. These
equations maintain that the probability of transitioning between all
possible states is 1, as graphically represented in Figure 2. This
means that there is a 100% probability that some transition will
occur.
For any given L§0, L-PSA is a Markov chain of order L. It is a
process satisfying P(stz1js1,:::,st)~P(stz1jst{L,:::,st), where
twL. We define the empirical probability of a sub-sequence s,
over the given sample set, as the number of times that the
subsequence was observed in the sample set divided by the
maximal number of (possibly overlapping) occurrences of a pattern
of the same length. The conditional empirical probability of
observing a state st right after a given sub-state sequence is defined
as the number of times that the state symbol appears after the
given subsequence divided by the total number of times that the
sub-sequence has appeared, followed by any state symbol.
Specifically, the frequencies f (si:::sj)of a sub-state sequence
si:::sj in the state sequences S~fsg is given by
f (si:::sj)~
P
(si:::sj), where si:::sj is a sub-sequence of S. The
conditional empirical probability of observing the state st right
after the state sequence si:::st{1 is defined by P(stjsi:::st{1), which
can be estimated using sub-state sequence frequencies as follows:
P(stjsi:::st{1)~ f (si:::st)
f (si:::st{1)
: ð5Þ
Note that this leads to a natural definition of a probability
distribution over all state sequences of length L since
Ss[SLP(s)~1.
As an example, consider a drug-pathogen state sequence
s~f1,2,3,1,2,3,2,1,3g with a three letter alphabet S~f1,2,3g.
Figure 2 shows the second-order PSA learned from the sequence.
The example PSA has eight possible states, namely, ‘‘Start’’, ‘‘1’’,
‘‘2’’, ‘‘3’’, ‘‘1_2’’, ‘‘2_1’’, ‘‘3_1’’, and ‘‘3_2’’. Note that ‘‘Start’’,
‘‘1’’, and ‘‘2’’ are transient states; ‘‘3’’, ‘‘1_2’’, ‘‘2_1’’, ‘‘3_1’’, and
‘‘3_2’’ are recurrent states. Detailed information on PSA
construction and inference procedures can be found in [23].
To model the normal behavior using the Maximum
Likelihood criterion, a model was developed that maximizes
the probability of a given sequence of observations. Specifically,
we let s~fst : t[Tg denote a temporal sequence of size T ,
where t denotes the discrete sampling time. Given a PSA l, the
total likelihood of the observations can be expressed mathe-
matically as P(sjl). Matching the drug concentration and
pathogen population states against a suffix automaton yields the
cumulative probability of the given state sequence being
generated by the PSA. To match a sequence against a PSA,
the algorithm starts with the first state symbol and finds its
corresponding state in the automaton. Next the model traverses
the sequence appending the next state symbol onto the previous
one. The algorithm then finds the current state based on the
newly created state label. If the node exists, the probability of
transitioning from the previous state to the current state is
noted, and the algorithm continues appending state symbols. If
the node does not exist, however, one symbol at a time is
removed from the front of the state label until a node is
encountered that does exist in the automaton. In the worst case,
the program will have to backtrack to a transient node, since it
should contain the next-symbol probability, in order to proceed
with the matching algorithm. In general terms, the PSA
searches the string of states for observations that have occurred
previously. If a state has previously occurred, then a new state is
not created, however, if the PSA searches the string and finds no
instances of the current state in the previous states, then a new
state is created.
The system can use the learned PSA model to predict the drug-
pathogen dynamics based on the current state st. The details of
the prediction are discussed in Section 1.4. If the probability of
the observation sequence given the model is below a threshold h,
obtained from the Receiver Operating Characteristic (ROC)
curve as described in detail in Section 2.4, then the drug
delivery method is categorized as ineffective. A likelihood-ratio
verification scheme has been created and is addressed in detail in
Section 1.5.
Figure 2. Example of second order PSA built from the state sequence, s~f1,2,3,1,2,3,2,1,3g. This state transition diagram shows the
probability of transitioning between states. The sum of all possible states transitions equals one, indicating that a state transition must occur.
doi:10.1371/journal.pone.0031724.g002
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1.4. Predict drug-pathogen dynamic using VLMM model
Given the drug-pathogen interaction state sequence, s its
prediction by a PSA model l can be conducted state by state,
where the cumulative probability in the sequence is calculated by
transitioning from one state to another, in a chainlike manner.
The problem can be formulated as follows: given a history, i.e., the
si:::st{1 sequence of t{1{i : iƒt{1 drug-pathogen interaction
states in the past, the method predicts the next drug-pathogen
dynamic state. The approach achieves the goal by finding the state
sm that maximizes the posterior probability of state sk. Formally it
is defined as follows,
st~sm if m~arg maxk P(skjsi:::st{1)~ f (si:::sk)
f (si:::st{1)
: ð6Þ
It is desirable to predict several consecutive drug-pathogen
dynamic states in a set window. A prediction window, of length L,
is defined as the prediction of a drug-pathogen state sequence
ststz1:::stzL{1 knowing its history s1s2:::st{1. The system can
achieve this by interactively predicting the next state and
appending the existing state sequence up to length L based on
past history.
Through the above approach, it will be possible to predict the
outcome of doses based on past sequence information. It will also
be possible to predict doses that have not been experimentally
tested as described in Section 2.2.
1.5 Predict drug delivery effectiveness using likelihood
ratio-based verification
To predict the effectiveness of a drug delivery strategy, a
likelihood-ratio based prediction method is used. In this example,
we assume that there is a training period, consisting of different
drug delivery methods in the training dataset. The effective drug
delivery methods are used to build a normal model, whereas
variations from the effective model are treated as an ineffective
drug delivery method. In this case we let s~fs’,s’’g denote the
entire drug delivery dataset, and s’ denote the normal training
drug delivery state sequences, while s’’ denotes the target testing
drug delivery state sequence. Given a sequence(s) of normal
training drug delivery trial(s) s’, and a sequence of testing drug
delivery states s’’, the task of verifying the effectiveness of a drug
delivery method can be formulated to determine if s’is the same as
s’’. Note that if the effective drug delivery methods are not
available, the random variable s’can represent an ineffective drug
delivery method, and an effective drug delivery method can be
detected when s’ matches s’’. The drug delivery verification
problem is formulated in the same manner. The task can be
restated as a hypothesis test between:
H0 : s’ is effective drug delivery
H1 : s’ is ineffective drug delivery

: ð7Þ
The likelihood-ratio test to decide between these two hypotheses is
given by:
p(s’jH0)
p(s’jH1)§h accept H0
p(s’jH0)
p(s’jH1)vh reject H0
8><
>:
, ð8Þ
where p(s’jHi), i~f0,1g, is the probability density function for the
hypothesis Hi evaluated for the observed sequence s’, also referred
to as the likelihood of the hypothesis Hi given the sequence. The
decision threshold for accepting or rejecting H0 is h. For our drug
delivery verification, the null and alternative hypothesis use PSA
models li. Hence, we denote the PSA model for the null hypothesis
as p(s’jH0; l0) and for the alternative hypothesis as p(s’jH1; l1).
The likelihood-ratio sequential verification process is given by
p(s’jH0; l0)=p(s’jH1; l1). Typically, the logarithm of this statistic is
used giving the log-likelihood ratio ‘,
‘~log p(s’jH0; l0){log p(s’jH1; l1): ð9Þ
During the training period, various drug delivery trials were
encountered that were effective, ineffective and/or undetermined. The
model for H0 was estimated using an effective event sequence.
However, the model forH1 was less well defined since it must represent
every ineffective drug delivery method. Since it is too expensive to run
every ineffective drug trial, it is not possible to train H1 with every
ineffective drug delivery method. Therefore, all hypothesized sequenc-
es of events, was a more suitable way to define H1.
1.6 System evaluation, sensitivity and specificity analysis
The following performance metrics were used to evaluate the
drug delivery verification system: True Positive Rate (TPR), True
Negative Rate (TNR), False Positive Rate (FPR), and False
Negative Rate (FNR). These performance metrics can be visualized
using a matrix. The matrix is often referred to as confusion matrix
(shown in Table 1). Ideally, the values of sensitivity and specificity
are at 100%; the values of false alarm rate and miss rate are at 0%.
The sensitivity and specificity of a diagnostic test depends on
more than just the ‘‘quality’’ of the test – they also depend on the
definition of what constitutes an abnormal test. In practice, we
choose a threshold h above which we consider the test to be
abnormal and below which we consider the test to be normal. The
position of the threshold will determine the number of true
positive, true negatives, false positives and false negatives. Different
thresholds can be used for different clinical situations if the goal is
to minimize one of the erroneous types of test results. A Receiver
Operating Characteristic curve was used to a guideline to balance
the tradeoff between sensitivity and specificity.
1.7 Experimental setup
Giardia lamblia trophozoites were obtained from the American
Type Culture Collection, strain designation 30957. Trophozoites
were grown and maintained anaerobically in modified Keister’s
media at pH 7.0, limiting cyst formation [24]. Eight doses, 0 mg/
ml, 1.9 mg/ml, 6.19 mg/ml, 10.95 mg/ml, 16.67 mg/ml, 20.4 mg/
ml, 32 mg/ml, and 50 mg/ml, were tested to provide a range of
Table 1. Performance metrics.
CONDITION (GOLD STANDARD)
POSITIVE NEGATIVE
Prediction
outcome
Positive True Positive False Positive
Negative False Negative True Negative
Sensitivity = TP/(TP+FN) Specificity = TN/(FP+TN)
Typical performance metrics table that reports the number of True Negatives,
False Positives, False Negatives, True Positives, Sensitivity and Specificity.
doi:10.1371/journal.pone.0031724.t001
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killing curves. Prior to the addition of drug, 105 cells/ml were
added to 2 ml glass screw cap tubes and incubated for 30 minutes
in a 37uC incubator. After this adjustment period, the drug was
added at time point 0 to the tubes and the cells were placed back
in the incubator. At 0, 4, 10, and 18 hours the cell number was
counted using a hemocytometer to determine the number of cells/
ml. This is a typical in vitro method used to determine the
effectiveness of drugs on G. lamblia, and has previously been
validated for determination of metronidazole activity specifically
[25,26,27,28,29]. All experiments were conducted in triplicate.
The half-life of metronidazole was estimated based on previous
pharmacokinetic data [30,31,32].
Results and Discussion
2.1 Experimental results
Killing curves were generated from the averaging of the three
replicates from each dose, examples of which are shown in
Figure 3 with the numerical data displayed in Table 2. In
addition to these curves, the data from each trial was plotted and
the points connected to illustrate the trend from each set of doses
(Figure S1). From this data, it was determined that the ineffective
doses were doses where the population at 18 hours was greater
than the starting population. In these curves, the cell population
Figure 3. Representative Giardia killing curves. Killing curves generated from the average of three replicates per dose. The cell counts were
compared to the control, which is typical of killing curves. Note that the general trend is towards an exponential decrease over the time interval of
the study, 18 hours. In the lowest dose tested, 1.9 mg/ml, an obvious plateau is reached at 18 hours indicating an ineffective dosing, while at the
other doses, the trend indicates a decline.
doi:10.1371/journal.pone.0031724.g003
Table 2. Cell number over time for each dose prior to pre-
processing.
Time interval (hours)
Dose (mg/ml) 1 4 10 18
0 16105 6.46104 4.16105 56105
1.9 16105 5.16104 1.26105 1.36105
6.19 8.56104 3.96104 1.66105 7.26104
10.95 1.26105 6.26104 1.56105 3.96104
16.67 1.16105 3.26104 1.16105 6.26104
20.4 8.96104 4.16104 7.16104 4.56104
32 96104 5.16104 1.26105 3.96104
50 8.16104 5.36104 8.66104 3.96104
The average cell count for each time interval and dose is displayed in the chart
above in cells/ml. As indicated in the methods, the starting cell concentration
was 16105 cells, however, variations always arise when making counts with a
hemocytometer. This data was used to generate the dose curves shown in
Figure 3.
doi:10.1371/journal.pone.0031724.t002
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was normalized to the starting population, i.e., starting cell
number/current cell number. Using this normalization, increases
in the cell number over time will have values greater than 100%,
whereas decreasing populations will have numbers less than 100%.
In terms of the biological implication of this normalization, if the
replication of trophozoites occurs every 8–12 hours [33], then if
the cell population is at the 100% threshold after 18 hours, when
the drug has significantly decayed, the population will continue to
increase and eventually reach a maximum population level. At the
initial time points, between 0 and 4 hours, all trials, including the
controls, exhibited a decline of similar proportions. This decline
was most likely due to a temperature effect that resulted in a
sampling error. Similarly, all trials displayed an increase in
population from 4 to 10 hours, although the degree of growth
varied. Since the effect of the drug is not immediate, and the cell
cycle was not synchronized, it was not surprising that a delay in
killing was observed in this study. An advantage of the system
developed in this study is that the system acts only to compare the
trends observed, allowing analysis of potentially misleading data at
the early stages. After acquiring the data from the experimental
studies, the data were preprocessed for incorporation into the
system for analysis and prediction.
2.2 Preprocessing
As described above, four sampling points were collected for
each drug trial and a killing curve was generated for each trial.
From each curve, data points were extrapolated for 2, 6, 8, 12, 14,
and 16 hours. In addition, the drug concentrations were
normalized based on the highest dose of 50 mg/ml administered.
The drug concentrations at each sampling point were estimated
using a 6 hour half-life for metronidazole [30,31]. The drug-
pathogen dynamics were classified into C~4 states. Hence, the
state sequence s had an alphabet size of jSj~4. The physical
meaning of the 4 states are defined as follows:
N current pathogen population (48,100%) with high
(24,50 mg/ml) drug concentration,
N current pathogen population (13,171%) with a medium
(7.65,20.4 mg/ml) drug concentration,
N current pathogen population (28,229%) with low
(0,6.84 mg/ml) drug concentration,
N and current pathogen population (267,702%) with low
(0,3.42 mg/ml) drug concentration.
Note that depending on the application, the user can choose the
desired number of states by setting the parameter C in the FCM
clustering algorithm.
Figure 4 displays an effective drug delivery method. The drug
concentration and cell population were categorized by the Fuzzy
C-Mean clustering algorithm as indicated by the colored boxes in
Figure 4. As illustrated in the figure, this trial started with a high
drug concentration and cell population of 100%, and transitioned
to a state with medium drug concentration and cell population
between 12,171%, and finally transitioned to the effective dosing
end state of low drug concentration and cell population from 28–
229%. Since the effective dosing all terminated in the same state, a
PSA was constructed for effective dosing using all effective trials,
Figure 5. In contrast, the ineffective dosing showed various
transitions between the states, and did not always terminate in the
same state. For this reason the PSAs for ineffective dosing (1.9 mg/
ml, 6.19 mg/ml and 10.95 mg/ml) were created by combining all
three trials of that dose. As an example, a PSA was constructed
based on the training data and an ineffective drug delivery method
combining all three trials at 1.9 mg/ml, shown in Figure 6. It
should be noted that the PSAs were built autonomously using the
developed system, and that the ‘‘start’’ and ‘‘end’’ states were
added for illustrative purposes only. As illustrated in Figure 5 and
Figure 6, the effective and ineffective drug delivery methods show
different temporal patterns. Based on analysis of the data, 15 trials
with effective dosing and 9 trials with ineffective dosing were
identified. Since, the overall goal of the study was to use the
learned PSA models to predict the drug-pathogen dynamics and
predict the effectiveness of an unknown drug delivery method; the
following experiments were conducted to demonstrate this
application and validate the developed model for realistic drug
delivery data.
2.3 Drug-pathogen dynamics prediction
In order to predict the drug-pathogen dynamics, the system uses
the Partial Prediction Matching (PPM) procedure, equation (6), on
the PSA model and the partial test sequence. To verify the ability
of the system to predict future drug-pathogen states, a 3-fold cross-
validation method was used on the available drug trials. As stated
in the experimental setup, three drug trials were conducted for
each dosing method, resulting in 24 individual trials. For each
round of cross validation, the 24 trials were partitioned into two
groups: training set and testing set. The training set contained
eight trials with one trial from each of the eight doses. The testing
set contained the other sixteen trials. To reduce variability,
multiple rounds of cross-validation were performed using different
partitions and the validation results were averaged over the
rounds. Table 3 shows the averaged prediction accuracies of 3-
fold cross validation for different partial matching sequence
lengths. The 3-fold cross validation for all trials was averaged to
determine the accuracy of the prediction at each observed
sequence length. As the observation sequence grew, the prediction
became more accurate, e.g., when the system received one
observation, the prediction accuracy was 53.33%; while when the
system received nine observations, the prediction accuracy
increased to 97.5%. Based on the available drug delivery trials,
the system had an accuracy greater than 73.33% when the
observation length was $4. It should be noted that the more data
points that are generated, the greater prediction efficiency over
time. The results from a Student’s T-test, assuming normal
distribution, comparing the accuracy of all observation lengths, i.e.
observation length 1 vs. 2, 1 vs. 3, etc., confirmed that the
difference in results were statistically significant (99.5% confidence
interval).
Table 4 shows the average prediction accuracies of 3-fold
cross-validation of drug delivery trials for each dosing method with
different partial matching sequence lengths. The average accuracy
for each observed sequence length was obtained from the average
of 3-fold partitions of drug delivery trials. The prediction
accuracies for each dosing method followed the same trend – as
the observation lengths grew, the system was able to predict more
accurately. This experiment also showed that some dosing
methods were easier to predict then others, e.g., a drug dose of
1.9 mg/ml had a prediction accuracy of 10% when only one
observation was available, while dose 6.29 mg/ml had a prediction
accuracy of 100% when only one observation was available. This
phenomenon was related to the complexity of the trend. Trends
with distinct features were easier to predict than ones that were not
as distinct.
The previous experiments demonstrate the system scalability
when all dosing methods are available. In practice, however, it is
not possible to test all drug dosing schemes. In a second
experiment, the training data contained five drug delivery methods
(control, 6.19 mg/ml, 16.67 mg/ml, 32 mg/ml, 50 mg/ml): two
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ineffective dosing methods (control, 6.19 mg/ml) and three
effective drug delivery methods (16.67 mg/ml, 32 mg/ml, 50 mg/
ml). After completion of the training phase, three doses (1.9 mg/
ml, 10.95 mg/ml, and 20.4 mg/ml), were evaluated. It should be
noted that the only data available to the model was the initial dose
and starting cell population, the sequences generated from the
experimental data were not available, and only used for
subsequent validation. For example in testing dose one (1.9 mg/
ml), the only state given to the model was the initial state
(s1:::::::::). The PSA then predicted the other 9 states based on this
initial state (s1). Next, the model was given two states (s1s2) from
the experimental data (s1s2::::::::)and the other 8 states were
predicted by the PSA. These iterations continued until all 10 states
from the experimental system were input into the model. To
evaluate the accuracy of the prediction of the PSA given variable
state lengths, the predicted state sequence was compared to the
experimental state sequence. Table 5 shows the prediction
accuracy based on the starting number of states given to the
Figure 4. An example of 50 mg/ml trial and its states. The separated boxes indicate different clusters/states. The width of the boxes indicates
the time duration of each state. The dotted curve represents the drug concentration over time, while the solid curve represents the percent change
of the pathogen over time.
doi:10.1371/journal.pone.0031724.g004
Figure 5. The Markov model state transition diagram built from the 15 effective drug delivery trials. The ‘‘start’’ and ‘‘end’’ states are
added for illustrative purposes. In the effective delivery strategy, it is possible to transition between three states. From the high drug state it is only
possible to remain in that state, or transition to the medium drug state. Similarly, once in the medium drug state it is not possible to transition back
to the high drug state, it is only possible to remain in that state or transition to the low drug state. Once in the low drug state, the system will remain
in the state for various iterations before finally ending.
doi:10.1371/journal.pone.0031724.g005
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model. As the observed sequence length increased, our system was
able to make more accurate predictions. It was determined that
the system needed at least four observations to have an accuracy of
,74%, based on the training dataset and partial observations. The
prediction accuracy of the system was 53% when only one
observation was given and 98% when eight observations were
given. Results from a student’s T-test again found that all results
were significant with a confidence level of 99.5%. The strong
significance of data with both analysis techniques indicates that the
system is able to accurately predict the future drug-pathogen
states, given an adequate sequence length.
In the context of the Giardia testing case that was used in this
paper, if experimental researchers were able to generate four
observations, the model would be able to accurately predict the
rest of the state sequences,74% of the time. This means that with
the training data used (control, 6.19 mg/ml, 16.67 mg/ml, 32 mg/
ml, 50 mg/ml) it would be possible to predict the effectiveness of all
treatments within this range, given these four initial points. When
trying to determine the trade-off between the effectiveness of
treatment while reducing the concentration of drug, this would
provide a complete set of data for mitigating this balance.
Experimentally testing all of these doses would be impossible, but
can quickly be achieved in silico using the system developed in this
study.
2.4 Model validation for prediction performance
To predict the effectiveness of a drug delivery trial, a likelihood
ratio-based verification technique was used, as defined in Equation
(9). In order to verify the performance of the prediction procedure,
the following procedure was used: during the training period, five
drug trials (control, 10.95 mg/ml, 32 mg/ml, 50 mg/ml) to obtain
the alternative hypothesis p(sjH1; l1), and the three effective drug
delivery methods (10.95 mg/ml, 32 mg/ml, 50 mg/ml) to obtain
the null hypothesis p(sjH0; l0). The learned universal PSA model
l1 consists of 80 nodes and the learned drug effective PSA model
l0 consists of 60 nodes. Two effective drug trials (16.67 mg/ml,
20.4 mg/ml) and two ineffective trials (1.9 mg/ml, and 6.19 mg/ml)
were used for testing the proposed prediction system. Each drug
trial was completed over 18 hours, and the data were expanded to
include 10 observation points. For each drug delivery method, the
state sequence length was incrementally increased to the drug trial
length T , where T~10, e.g., s~fs1,s1s2,s1s2s3,:::g and the log
likelihood-ratios were obtained for the tested drug-pathogen state
sequences, i.e., P~fps1 ,ps1s2 ,ps1s2s3 ,:::g.
In order to determine the verification threshold h, a Receiver
Operating Characteristic curve was used. The ROC curve plots
the TPR/sensitivity vs. the FPR/false alarm rate for a binary
verification (2-class) system as its verification threshold is varied.
Figure 7 shows the ROC curve constructed from the testing
trials. Note that each prediction result (or one instance of a
confusion matrix) represents one point in the ROC space. The
best possible prediction has no false negatives or false positives.
From Figure 7, it was observed that the optimal operating point
Figure 6. The Markov model state transition diagram built from an ineffective drug delivery. The ‘‘start’’ and ‘‘end’’ states are added for
illustrative purpose. In this example of ineffective delivery, the model has only two transition states. When the concentration of drug is low and the
current population is below the starting population, the system is more likely to remain in this state for several iterations. Eventually, however, a
transition out of this state will occur resulting in a low drug concentration and a larger current population. Once in this state it is impossible to leave
this state, and eventually an end state will be reached.
doi:10.1371/journal.pone.0031724.g006
Table 3. The prediction performance of 3-fold cross-
validation for all doses.
Observed
sequence
length 1 2 3 4 5 6 7 8 9
Accuracy (Mean) 53.33 60.83 67.08 73.33 79.58 85.0 90.0 93.75 97.50
Accuracy
(Variance)
8.91 8.25 7.1 6.44 4.72 3.1 2.0 1.79 0.08
The averaged prediction accuracies for variable sequence lengths for all dosing
methods. (control, 1.9 mg/ml, 6.19 mg/ml, 10.95 mg/ml, 16.67 mg/ml, 20.4 mg/ml,
32 mg/ml, and 50 mg/ml).
doi:10.1371/journal.pone.0031724.t003
Table 4. The average prediction accuracies of 3-fold cross-
validation for each dose.
Observed
sequence
length 1 2 3 4 5 6 7 8 9
Control 40.0 40.0 40.0 40.0 50.0 60.0 70.0 80.0 90.0
1.90 mg/ml 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0
6.19 mg/ml 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
10.95 mg/ml 86.7 96.7 96.7 96.7 100.0 100.0 100.0 100.0 100.0
16.67 mg/ml 70.0 80.0 90.0 100.0 100.0 100.0 100.0 100.0 100.0
20.40 mg/ml 60.0 70.0 80.0 90.0 100.0 100.0 100.0 100.0 100.0
32.00 mg/ml 40.0 50.0 60.0 70.0 80.0 90.0 100.0 100.0 100.0
50.00 mg/ml 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
The prediction accuracy based on sequence length shows a similar trend
observed when all of the curves were averaged. As the sequence length
increases for each does, the prediction accuracy increases. The only exception is
the dose of 6.19 mg/ml, where the accuracy is 100% because this dose does not
transition out of the initial state. In cases with more complex transitions, a larger
sequence length is needed for accurate predictions.
doi:10.1371/journal.pone.0031724.t004
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for the proposed verification system has a TPR of 80% and a FPR
of 20%. This optimal operating point (TPR= 80%, FPR= 20%)
was used as the reference to set the likelihood-ratio threshold h
value in Equation (8). Table 6 shows the sensitivities and
specificities obtained when adjusting the threshold parameter h.
The threshold value of h~0:8179 gives the optimal trade-off
between sensitivity and specificity in our drug delivery test
environment. As mentioned previously, depending on the
application, different threshold values can be used to meet the
user requirements. In the current test case, the AUC for the
generated ROC curve was found to be 85%. The current
experimental setup has validated that the developed system is able
to predict the effectiveness of unseen drug delivery methods with
good performance (accuracy ,85%). In addition, the system is
adaptable to multiple applications. For example, if the drug
delivery task requires high specificity (i.e., ,100%) with low
sensitivity (i.e.,,50%), the system can adjust the threshold to 1.25.
In this way the system is robust for a variety of applications, and
can be tuned by an operator.
In summary, the developed system is able to predict the future
drug-pathogen dynamics based on current observations. Our
experimental results have shown that the prediction performance
is able achieve 74% when four observations are made. In addition,
our developed system is able to predict the effectiveness of a drug
dosing method in silico based on the current observations of the
environment with high performances. Our experimental results
have shown that they system is able to obtain an overall accuracy
of 85%. In addition, the system is able to achieve 80% of true
positive rate and 20% of false positive rate for the optimal trade-off
point. Depends on the application, users can adjust the threshold
to achieve higher true positive rate or false positive rate. The
learning system is able to cluster the drug-pathogen dynamics into
discrete states and analysis the temporal dependencies among the
state in a fully autonomous fashion.
2.5 Conclusion
In this paper, we have developed a machine learning framework
that models the drug-pathogen dynamics. The framework can be
used to test the outcome of a variety of doses given a limited
number of experimental data. The proposed framework has been
validated in vitro through experimental study with Giardia lamblia.
Based on the framework, the system first learns to categorize the
drug-pathogen interactions into a discrete set of states using a
Fuzzy C-Mean clustering algorithm. It then uses a PSA to model
the temporal state sequences. The learned models can be used to
predict the drug-pathogen dynamics based on the past history. In
addition, a likelihood-ratio verification method was used to predict
the effectiveness of a given drug delivery method. Due to the
experimental limitations, the data collected is often noisy and
incomplete. Therefore, online, unsupervised, data-driven methods
were chosen. This proposed method was validated experimentally
for the drug/cell interaction between Giardia lamblia and
metronidazole. Using the method, it was possible to predict the
dynamic drug-cell states over time, and the effectiveness of the
treatment strategy. The accuracy of prediction increased from
73% with four data points to 97.5% with nine data points.
Performance evaluation of the system, when predicting the
effectiveness of the strategy, revealed an accuracy of 85%, using
an ROC method. This system can predict the effectiveness of
multiple dosing schemes, allowing for reduced experimental costs,
Figure 7. The ROC curve for determining prediction perfor-
mance. The ROC curve shows the tradeoff between sensitivity and
specificity (any increase in sensitivity will be accompanied by a decrease
in specificity). The closer the curve is to the minimum false alarm rate (x-
axis) and the maximum sensitivity (y-axis), the more accurate the test.
As the ROC curve approaches y = x, the less accurate the test becomes.
The intersection point of the ROC curve with the line y =2x is defined
as the optimum operation point. In this ROC curve, the optimum
operation point had an 80% true positive rate, with a 20% false positive
rate.
doi:10.1371/journal.pone.0031724.g007
Table 6. Thresholds for different trade-offs.
Threshold h Sensitivity 1-Specificity
… … …
0.8179 0.8000 0.2000
0.8601 0.8000 0.3000
0.8864 0.8000 0.4000
0.9044 0.8000 0.5000
… … …
1.2462 0.5000 1.0000
… … …
Different sensitivities and specificities of the prediction system by adjusting
threshold values. For example, if a threshold of 0.8179 is selected, then the
sensitivity predicts performance would be 80% and the rate of getting the false
alarm rate is 20%.
doi:10.1371/journal.pone.0031724.t006
Table 5. The prediction performance for in silico dosing.
Observed
sequence
length 1 2 3 4 5 6 7 8 9
% Accuracy
(Mean)
52.5 60.0 67.5 73.8 80.0 85.0 90.0 93.8 97.5
% Accuracy
(Variance)
9.4 8.6 8.2 7.4 5.4 3.4 2.0 0.8 0.2
Average prediction accuracies based on the training data sets (control, 6.19 mg/
ml, 16.67 mg/ml, 32 mg/ml, 50 mg/ml) and the testing data sets (1.9 mg/ml,
10.95 mg/ml, and 20.4 mg/ml).
doi:10.1371/journal.pone.0031724.t005
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and an increased speed of prediction. This will allow researchers to
investigate more effective treatment options by evaluating a larger
pool of doses than possible with experiments. It will also be
possible for a user to adjust the treatment, if the current treatment
has been determined to be ineffective. In this way it will be possible
to monitor patient non-compliance by monitoring the drug dose
and pathogen population on a return visit to determine the
effectiveness of the treatment. Future work will use a Markov
Decision Process to separate the dose into discrete actions, based
on the observations of pathogen population and side effects, the
system will then decide to increase or decrease the dosage.
Throughout this process an optimum dosing strategy could be
learned, balancing the trade-off between side-effects, pathogen
population, and the dosage.
Supporting Information
Figure S1 Giardia killing trends from various doses of
metronidazole. The Giardia staring population was normalized
to 100%. The Giardia cells were counted at hours 0, 4, 10, and 18
and were normalized based on control. Eight doses were used,
0 mg/ml, 1.9 mg/ml, 6.19 mg/ml, 10.95 mg/ml, 16.67 mg/ml,
20.4 mg/ml, 32 mg/ml, and 50 mg/ml. Three drug delivery trials
were conducted for each dose.
(TIF)
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